AHA Scientific Sessions 2026 Abstract
Weighted blood marker better predicted heart and stroke risk
Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.

Randomized trial · 11,957 peopleBiomarkers
Who was studied11,957 statin-treated patients with recent acute coronary syndrome
What changedThe weighted blood marker predicted heart and stroke events better than apolipoprotein B or lipoprotein(a) alone among placebo recipients
The catchPrediction curves did not account for other patient differences affecting risk or treatment benefit




